Nosirudeen Quadri

Regeneron (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index2.7kcitations30works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Glycation End Products research(10), Aldose Reductase and Taurine(9), Cardiac Ischemia and Reperfusion(8), Cardiovascular Function and Risk Factors(4), Cardiac Arrest and Resuscitation(3)

Publications30 total

Abstract 4365510: Platelet-derived growth factor antagonist antibody attenuates pulmonary arterial hypertension and prevents right heart dysfunction in the Sugen-Hypoxia rat model
Circulation·2025
THE IMPACT OF PLATELET-DERIVED GROWTH FACTOR-BB ANTAGONIST ANTIBODY ON RIGHT HEART FAILURE IN PULMONARY HYPERTENSION IN PRECLINICAL ANIMAL STUDIES
CHEST Journal·2025
Agonist Antibody to Natriuretic Peptide Receptor 1 for CKD
Journal of the American Society of Nephrology·2025
Assessment of cardiac and skeletal muscle metabolites using <sup>1</sup>H‐MRS and chemical‐shift encoded magnetic resonance imaging: Impact of diabetes, RAGE, and DIAPH1
NMR in Biomedicine·2024· 2 citedOpen Access
DIAPH1-MFN2 interaction regulates mitochondria-SR/ER contact and modulates ischemic/hypoxic stress
Nature Communications·2023· 44 citedOpen Access
Abstract P3086: Aldose Reductase Deletion Protects Ischemic Murine Hearts By Modulating Immune Cell Dynamics
Circulation Research·2023
Aldose reductase promotes diet‐induced obesity via induction of senescence in subcutaneous adipose tissue
Obesity·2022· 11 cited
Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice
Science Translational Medicine·2021· 69 citedOpen Access
1080-P: Addressing the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy, a Potent and Selective Next Generation Aldose Reductase Inhibitor
Diabetes·2020· 5 cited
462-P: AT-001, a Next Generation Aldose Reductase Inhibitor with Improved Selectivity and Specificity, Protects from Cellular Damage Associated with Hyperglycemia
Diabetes·2020· 3 cited
Novel Therapeutic Opportunities for Diabetic Complications using a Small Molecule Antagonist of RAGE/DIAPH1 Interaction
The FASEB Journal·2020
Overcoming the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy
Metabolism·2020· 1 cited
RAGE‐DIAPH1 modulates hyperglycemia driven induction of Serum response factor target genes in cardiac cells
The FASEB Journal·2019
Small Molecule Antagonists of RAGE‐DIAPH1: Novel Therapeutic Opportunities in Metabolic and Chronic Disease
The FASEB Journal·2018
Aldose reductase modulates acute activation of mesenchymal markers via the β-catenin pathway during cardiac ischemia-reperfusion
PLoS ONE·2017· 4 citedOpen Access
The Formin, DIAPH1, is a Key Modulator of Myocardial Ischemia/Reperfusion Injury
EBioMedicine·2017· 40 citedOpen Access
Effects of Acute n‐3 Fatty Acid Administration on Cardiac Lipid Metabolism and Ca <sup>2+</sup> Homeostasis during Ischemia‐Reperfusion
The FASEB Journal·2016
Aldose Reductase Acts as a Selective Derepressor of PPARγ and the Retinoic Acid Receptor
Cell Reports·2016· 27 citedOpen Access
Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction
Scientific Reports·2016· 105 citedOpen Access
Glutaminolysis and Transferrin Regulate Ferroptosis
Molecular Cell·2015· 1.9k citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Ravichandran Ramasamy(22), Ann Marie Schmidt(18), Radha Ananthakrishnan(13), Alexander Shekhtman(6), Qing Li(6), Gautham Yepuri(6), Hylde Zirpoli(6), Rosa Rosario(5), Michaele B. Manigrasso(5), Devi Thiagarajan(5), Karen M. O’Shea(5), Robert J. DeVita(4), Mariane Abdillahi(4), Syed Nurul Hasan(4), Lingjie Wang(4), Wu Qu(3), Vivette D. D’Agati(3), Zhengbin Zhu(3), Ravichandran Ramasamy(3), Gopalkrishna Sreejit(3)